| Overview |
| bs-3687R-Cy7 |
| OGG1 Polyclonal Antibody, Cy7 Conjugated |
| WB, FCM |
| Human, Mouse, Rat |
| Dog, Cow, Pig |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human OGG1/8 hydroxyguanine DNA glycosylase |
| 151-250/424 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 4968 |
| Cytoplasm, Nucleus |
| 8 hydroxyguanine DNA glycosylase; 8 oxoguanine DNA glycosylase 1; 8-oxoguanine DNA glycosylase; AP lyase; DNA apurinic or apyrimidinic site lyase; DNA lyase; DNA-apurinic or apyrimidinic site lyase; HMMH; HOGG 1; HOGG1; MMH; MUTM; N-glycosylase; Ogg 1; OGH 1; OGH1; OGG1_HUMAN. |
| This gene encodes the enzyme responsible for the excision of 8-oxoguanine, a mutagenic base byproduct which occurs as a result of exposure to reactive oxygen. The action of this enzyme includes lyase activity for chain cleavage. Alternative splicing of the C-terminal region of this gene classifies splice variants into two major groups, type 1 and type 2, depending on the last exon of the sequence. Type 1 alternative splice variants end with exon 7 and type 2 end with exon 8. All variants share the N-terminal region in common, which contains a mitochondrial targeting signal that is essential for mitochondrial localization. Many alternative splice variants for this gene have been described, but the full-length nature for every variant has not been determined. [provided by RefSeq, Aug 2008]. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
Powered by Bioz